Roche has provided the results from the international phase III study NO16968 (Xeloxa), investigating oral Xeloda in combination with intravenous oxaliplatin (Xelox) immediately after surgery. The study showed
Idenix has completed a three-day proof-of-concept study of IDX184. The company is developing IDX184, a novel liver-targeted prodrug of 2′-methyl guanosine nucleotide, for the treatment of Hepatitis C
ImClone and Bristol-Myers Squibb has announced that the FDA has approved revisions to the US prescribing information for ERBITUX (cetuximab). It is concerned with the treatment of patients
Asuragen has entered into an agreement with Biogen Idec to identify a potential companion diagnostic test, that may be used to select patients likely to respond to a
Generex has published the results from preclinical studies, demonstrating the anti-cancer activity of a novel Ii-Key/HPV immunotherapeutic vaccine. The immunotherapeutic vaccine for HPV-induced cancers make use of the
Mylan Pharmaceuticals has received approval from the FDA for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10mg and 20mg. These strengths are in addition
FDA has accepted to review AP Pharma’s New Drug Application (NDA) for APF530, for the potential treatment of chemotherapy-induced nausea and vomiting (CINV). APF530 is a long-acting formulation
Vertex Pharmaceuticals, a biotechnology company, has completed its acquisition of ViroChem Pharma, a privately-held company with two investigational HCV polymerase inhibitors in clinical development. ViroChem shareholders received $100
Astellas has established Astellas Farma Brasil Importacao e Distribuicao de Medicamentos, in Sao Paulo, Brazil, to help meet the growing demand for pharmaceuticals in the country. The facility
CytRx has announced that treatment with its cancer drug candidate INNO-206 resulted in a statistically significant reduction in the average primary tumor size in an animal model of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.